Nadia Alfaidy

Dr. Nadia Alfaidy

INSERM U1036, UMR Biosanté, CEA Grenoble & University of Grenoble-Alpes, France
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2008 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
PHPascale Hoffmann
Pascale Hoffmann
YSYasmina Saoudi
Yasmina Saoudi
MBMohamed Benharouga
Mohamed Benharouga
CGCharles H. Graham
Charles H. Graham
JSJean‐Patrick Schaal
Jean‐Patrick Schaal
Nadia AlfaidyNadia Alfaidy
Nadia Alfaidy
Pre‐eclampsia (PE), the major cause of maternal morbidity and mortality, is thought to be caused by shallow invasion of the maternal decidua by extravillous trophoblasts (EVT). Data suggest that a fine balance between the expressions of pro‐ and anti‐invasive factors might regulate EVT invasiveness. Recently, we showed that the expression of the new growth factor endocrine gland‐derived vascular endothelial growth factor (EG‐VEGF) is high in early pregnancy but falls after 11 weeks, suggesting an essential role for this factor in early pregnancy. Using human villous explants and HTR‐8/SVneo, a first trimester extravillous trophoblast cell line, we showed differential expression of EG‐VEGF receptors, PKR1 and PKR2, in the placenta and demonstrated that EG‐VEGF inhibits EVT migration, invasion and tube‐like organisation. EG‐VEGF inhibitory effect on invasion was supported by a decrease in matrix metalloproteinase (MMP)‐2 and MMP‐9 production. Interference with PKR2 expression, using specific siRNAs, reversed the EG‐VEGF‐induced inhibitory effects. Furthermore, we determined EG‐VEGF circulating levels in normal and PE patients. Our results showed that EG‐VEGF levels were highest during the first trimester of pregnancy and decreased thereafter to non‐pregnant levels. More important, EG‐VEGF levels were significantly elevated in PE patients compared with age‐matched controls. These findings identify EG‐VEGF as a novel paracrine regulator of trophoblast invasion. We speculate that a failure to correctly down‐regulate placental expression of EG‐VEGF at the end of the first trimester of pregnancy might lead to PE.

15 August 2010 in Molecular Biology of the Cell
Verified
Journal Article
Open access
SBSophie Brouillet
Sophie Brouillet
PHPascale Hoffmann
Pascale Hoffmann
MBMohamed Benharouga
Mohamed Benharouga
ASAude Salomon
Aude Salomon
JSJean-Patrick Schaal
Jean-Patrick Schaal
Nadia AlfaidyNadia Alfaidy
Nadia Alfaidy
Endocrine gland derived vascular endothelial growth factor (EG-VEGF) also called prokineticin (PK1), has been identified and linked to several biological processes including angiogenesis. EG-VEGF is abundantly expressed in the highest vascularized organ, the human placenta. Here we characterized its angiogenic effect using different experimental procedures. Immunohistochemistry was used to localize EG-VEGF receptors (PROKR1 and PROKR2) in placental and umbilical cord tissue. Primary microvascular placental endothelial cell (HPEC) and umbilical vein-derived macrovascular EC (HUVEC) were used to assess its effects on proliferation, migration, cell survival, pseudovascular organization, spheroid sprouting, permeability and paracellular transport. siRNA and neutralizing antibody strategies were used to differentiate PROKR1- from PROKR2-mediated effects. Our results show that 1) HPEC and HUVEC express both types of receptors 2) EG-VEGF stimulates HPEC's proliferation, migration and survival, but increases only survival in HUVECs. and 3) EG-VEGF was more potent than VEGF in stimulating HPEC sprout formation, pseudovascular organization, and it significantly increases HPEC permeability and paracellular transport. More importantly, we demonstrated that PROKR1 mediates EG-VEGF angiogenic effects, whereas PROKR2 mediates cellular permeability. Altogether, these data characterized angiogenic processes mediated by EG-VEGF, depicted a new angiogenic factor in the placenta, and suggest a novel view of the regulation of angiogenesis in placental pathologies.

15 February 2014 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
AHA. C. Holloway
A. C. Holloway
ASA. Salomon
A. Salomon
MSM. J. Soares
M. J. Soares
VGV. Garnier
V. Garnier
Sandeep RahaSandeep Raha
Sandeep Raha
Nadia AlfaidyNadia Alfaidy
Nadia Alfaidy
In utero exposure to nicotine is associated with increased risk of numerous adverse fetal and neonatal outcomes, which suggests that it acts directly to affect placental development and the establishment of the fetomaternal circulation (FC). This study used both in vivo [Wistar rats treated with 1 mg/kg nicotine from 2 wk prior to mating until gestational day (GD) 15] and in vitro (RCHO-1 cell line; treated with 10−9to 10−3M nicotine) models to examine the effects of nicotine on these pathways. At GD 15, control and treated placentas were examined for the impact of nicotine on 1) trophoblast invasion, proliferation, and degree of hypoxia, 2) labyrinth vascularization, 3) expression of key genes of placental development, and 4) expression of placental angiogenic factors. The RCHO-1 cell line was used to determine the direct effects of nicotine on trophoblast differentiation. Our in vivo experiments show that nicotine inhibits trophoblast interstitial invasion, increases placental hypoxia, downregulates labyrinth vascularization as well as key transcription factors Hand1 and GCM1, and decreases local and circulating EG-VEGF, a key placental angiogenic factor. The in vitro experiments confirmed the inhibitory effects of nicotine on the trophoblast migration, invasion, and differentiation processes and demonstrated that those effects are most likely due to a dysregulation in the expression of nicotine receptors and a decrease in MMP9 activity. Taken together, these data suggest that adverse effects of maternal smoking on pregnancy outcome are due in part to direct and endocrine effects of nicotine on the main processes of placental development and establishment of FC.

3 December 2011 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
SBSophie Brouillet
Sophie Brouillet
PHP. Hoffmann
P. Hoffmann
SCS. Chauvet
S. Chauvet
ASA. Salomon
A. Salomon
SCS. Chamboredon
S. Chamboredon
Nadia AlfaidyNadia Alfaidy
Nadia Alfaidy

2 September 2012 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
SBSophie Brouillet
Sophie Brouillet
PMP. Murthi
P. Murthi
PHP. Hoffmann
P. Hoffmann
ASA. Salomon
A. Salomon
FSF. Sergent
F. Sergent
Nadia AlfaidyNadia Alfaidy
Nadia Alfaidy

21 April 2022 in Cells
Verified
Journal Article
Open access
PDF file
IAIrvan Alfian
Irvan Alfian
Amlan ChakrabortyAmlan Chakraborty
Amlan Chakraborty
HYHannah E.J. Yong
Hannah E.J. Yong
SSSheetal Saini
Sheetal Saini
RLRicky W. K. Lau
Ricky W. K. Lau
Padma MurthiPadma Murthi
Padma Murthi
Fetal growth restriction (FGR) is commonly associated with placental insufficiency and inflammation. Nonetheless, the role played by inflammasomes in the pathogenesis of FGR is poorly understood. We hypothesised that placental inflammasomes are differentially expressed and contribute to the aberrant trophoblast function. Inflammasome gene expression profiles were characterised by real-time PCR on human placental tissues collected from third trimester FGR and gestation-matched control pregnancies (n = 25/group). The functional significance of a candidate inflammasome was then investigated using lipopolysaccharide (LPS)-induced models of inflammation in human trophoblast organoids, BeWo cells in vitro, and a murine model of FGR in vivo. Placental mRNA expression of NLRP3, caspases 1, 3, and 8, and interleukin 6 increased (>2-fold), while that of the anti-inflammatory cytokine, IL-10, decreased (2-fold) in trophoblast organoids and BeWo cell cultures in vitro, and in the spongiotrophoblast and labyrinth in the murine model of FGR. However, the LPS-induced rise in NLRP3 was attenuated by its siRNA-induced down-regulation in BeWo cell cultures, which correlated with reduced activity of the apoptotic markers, caspase-3 and 8, compared to the control siRNA-treated cells. Our findings support the role of the NLRP3 inflammasome in the inflammation-induced aberrant trophoblast function, which may contribute to FGR.